Evidence mapPaperPMID 33459178Full record

ArticleAmerican journal of physiology. Endocrinology and metabolism2021

The prorenin receptor and its soluble form contribute to lipid homeostasis.

Eva Gatineau, Gertrude Arthur, Audrey Poupeau, Kellea Nichols, Brett T Spear, Nathan R Shelman, Gregory A Graf, Ryan E Temel, Frédérique B Yiannikouris

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Endocrinology and metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Eva GatineauDepartment of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, Kentucky.
Gertrude ArthurDepartment of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, Kentucky.
Audrey PoupeauDepartment of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, Kentucky.
Kellea NicholsDepartment of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, Kentucky.
Brett T SpearDepartment of Microbiology, Immunology and Molecular Genetics, University of Kentucky, Lexington, Kentucky.
Nathan R ShelmanDepartment of Pathology & Laboratory Medicine, University of Kentucky, Lexington, Kentucky.
Gregory A GrafDepartment of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky.
Ryan E TemelCardiovascular Research Center and Department of Physiology, University of Kentucky, Lexington, Kentucky.
Frédérique B YiannikourisDepartment of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, Kentucky.
University of Kentucky · US

Funding

Kentucky Center for Clinical and Translational ScienceUL1TR001998 · UNIVERSITY OF KENTUCKY · 2025 to 2025
$3.3M
Contributions of Hepatic and Intestinal Pathways to Cholesterol ExcretionR01DK113625 · UNIVERSITY OF KENTUCKY · 2025 to 2025
$492k
CCTS, pilot grant, PI, Frederique Yiannikouris UL1TR001998NCATS NIH HHS UL1 TR001998NHLBI NIH HHS R01 HL142969NIDDK NIH HHS R01 DK113625NIGMS NIH HHS P30 GM127211
6 · The paper itself

Abstract

Obesity is associated with alterations in hepatic lipid metabolism. We previously identified the prorenin receptor (PRR) as a potential contributor to liver steatosis. Therefore, we aimed to determine the relative contribution of PRR and its soluble form, sPRR, to lipid homeostasis. PRR-floxed male mice were treated with an adeno-associated virus with thyroxine-binding globulin promoter-driven Cre to delete PRR in the liver [liver PRR knockout (KO) mice]. Hepatic PRR deletion did not change the body weight but increased liver weights. The deletion of PRR in the liver decreased peroxisome proliferator-activated receptor gamma (PPARγ) and triglyceride levels, but liver PRR KO mice exhibited higher plasma cholesterol levels and lower hepatic low-density lipoprotein receptor (LDLR) and Sortilin 1 (SORT1) proteins than control (CTL) mice. Surprisingly, hepatic PRR deletion elevated hepatic cholesterol, and up-regulated hepatic sterol regulatory element-binding protein 2 (SREBP2) and 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA-R) genes. In addition, the plasma levels of sPRR were significantly higher in liver PRR KO mice than in controls. In vitro studies in HepG2 cells demonstrated that sPRR treatment upregulated SREBP2, suggesting that sPRR could contribute to hepatic cholesterol biosynthesis. Interestingly, PRR, total cleaved and noncleaved sPRR contents, furin, and Site-1 protease (S1P) were elevated in the adipose tissue of liver PRR KO mice, suggesting that adipose tissue could contribute to the circulating pool of sPRR. Overall, this work supports previous works and opens a new area of investigation concerning the function of sPRR in lipid metabolism and adipose tissue-liver cross talk.

Indexed as

Adipose TissueAnimalsFatty LiverHep G2 CellsHomeostasisHumansLipid MetabolismLiverMaleMiceMice, KnockoutObesityProrenin ReceptorProtein IsoformsReceptors, Cell SurfaceSolubilityProrenin ReceptorProtein IsoformsReceptors, Cell SurfaceTriglyceridesadipose tissuelipid homeostasisliverPRRsPRR

Identifiers

PMID33459178
PMCPMC7988779
OpenAlexW3123804728

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.